EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

In silico evaluation of a beta‐lactam dosing guideline among adults with serious infections

Paul Williams iD, Menino Osbert Cotta iD, Mohd H Abdul-Aziz iD, Kathryn Wilks, Andras Farkas, Jason A Roberts iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023

DOI: 10.1002/phar.2753 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Verfasst von Paul Williams und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Lactams. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Advancing Queensland Clinical Fellowship, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objective The aim of this study was to compare the achievement of therapeutic pharmacokinetic–pharmacodynamic (PK‐PD) exposure targets for beta‐lactam antibiotics using product information dosing or guideline‐based dosing for the treatment of serious infections.

Design

In silico study. Data Source ID‐ODS TM (Individually Designed Optimum Dosing Strategies). Patients and Intervention None. Measurements and Main Results In silico product information and guideline‐based dosing simulations for cefepime, ceftazidime, flucloxacillin, meropenem, and piperacillin/tazobactam were performed using pharmacokinetic models from seriously ill patient populations. The median simulated concentration at 48 and 96 h was used to measure the probability of target attainment (PTA) to achieve predefined therapeutic and toxicity PK‐PD targets. A multiple linear regression model was constructed to identify the effect of guideline‐based dosing covariates on achieving pre‐defined therapeutic targets. In total, 480 dosing simulations were performed. The PTA percentage with guideline‐based dosing at 48 and 96 h was 80% and 68%, respectively, yielding significantly higher results when compared to product information dosing (48.45% and 49%, respectively), p < 0.001 at both time points. At 48 h, predefined toxicity thresholds were exceeded in 4.7% and 0% of simulations for guideline‐based and product information‐based dosing, respectively ( p = 0.002). eGFR was significantly associated with the % PTA by guideline‐based dosing, with eGFR values of 20 and 50 ml/min both statistically significant in leading to an increase in PTA.

Conclusions

Our study demonstrated that achievement of PK‐PD exposures associated with an increased likelihood of effectiveness was more likely to occur with guideline‐based dosing; especially at 48 h.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsLactamsAdultHumansMeropenemCefepimeCeftazidimeCritical IllnessMicrobial Sensitivity Tests

Stichwörter der Autor:innen

beta-lactamcritically illguidelinenomogram

Substanzen

Anti-Bacterial AgentsLactamsMeropenemCefepimeCeftazidime

Autor:innen und Institutionen

  • University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane, Queensland, Australia.
  • Pharmacy Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia.
  • Infectious Diseases Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia.
  • School of Public Health, The University of Queensland, Brisbane, Queensland, Australia.
  • Department of Pharmacy, Mount Sinai West, New York, New York, USA.
  • Optimum Dosing Strategies, Bloomingdale, New Jersey, USA.

ORCID-Profile: Paul Williams, Menino Osbert Cotta, Mohd H Abdul-Aziz, Jason A Roberts

Förderung

  • Advancing Queensland Clinical Fellowship
  • National Health and Medical Research Council

Zitieren

APA

Williams, P., Cotta, M. O., Abdul-Aziz, M. H., Wilks, K., Farkas, A., & Roberts, J. A. (2023). In silico evaluation of a beta‐lactam dosing guideline among adults with serious infections. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2753

Vancouver

Williams P, Cotta MO, Abdul-Aziz MH, Wilks K, Farkas A, Roberts JA. In silico evaluation of a beta‐lactam dosing guideline among adults with serious infections. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2753

BibTeX
@article{Williams2023,
  author = {Williams, Paul and Cotta, Menino Osbert and Abdul-Aziz, Mohd H and Wilks, Kathryn and Farkas, Andras and Roberts, Jason A},
  title = {In silico evaluation of a beta‐lactam dosing guideline among adults with serious infections},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  doi = {10.1002/phar.2753}
}
Kostenlos starten →